Laura A. Aparicio-Vallejo
Tres Cantos, MD 28760, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Potential healthcare resource use and associated costs of every 2 month injectable cabotegravir plus rilpivirine long-acting regimen implementation in the Spanish National Healthcare System compared to daily oral HIV treatments.
Journal: BMC infectious diseases
Published: January 17, 2024
Contribution of cabotegravir + rilpivirine long-acting for the treatment of HIV-1 infection.
Journal: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria
Published: October 02, 2022
Societal Preferences for Meningococcal B Vaccination in Children: A Discrete Choice Experiment in Spain.
Journal: Infectious diseases and therapy
Published: August 03, 2022
Direct Medical Costs of Four Vaccine-Preventable Infectious Diseases in Older Adults in Spain.
Journal: PharmacoEconomics - open
Published: February 01, 2022
Correction to: Cost-consequence analysis of fluticasone furoate/vilanterol for asthma management in Spain: an analysis based on the Salford Lung Study in asthma.
Journal: The European journal of health economics : HEPAC : health economics in prevention and care
Published: December 06, 2019
Cost-consequence analysis of fluticasone furoate/vilanterol for asthma management in Spain: an analysis based on the Salford Lung Study in asthma.
Journal: The European journal of health economics : HEPAC : health economics in prevention and care
Published: December 03, 2018
Cost-consequence analysis of fluticasone furoate/vilanterol 92/22 mcg for the management of COPD in the Spanish NHS.
Journal: ClinicoEconomics and outcomes research : CEOR
Published: September 21, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026